Broad Institute signs deals to boost medical research
12-10-2017
adike / shutterstock.com
An interference proceeding on the patent rights to CRISPR/Cas9 will take place on December 6, with the judges setting the definition of the disputed invention as “the use of CRISPR in a method in a eukaryotic cell”.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
CRISPR, CRISPR/Cas9, UCB, patent, USPTO, Broad Institute, MIT, Harvard